Harwin Peter Evan 4

What Happened
Harwin Peter Evan, a director of Cogent Biosciences (COGT), received a grant of 17,901 derivative securities (stock options) on 2026-06-09. The reported acquisition price is $0, so there was no cash exchanged at grant. The options are an award (not a purchase or sale) and therefore do not represent an immediate change in market position.

Key Details

• Transaction date: 2026-06-09; Form 4 filed: 2026-06-11 (timely within the two-business-day window).
• Transaction type: A (Award/Grant of derivative securities).
• Shares/options granted: 17,901; reported price: $0 (no immediate cash value).
• Shares owned after transaction: Not specified in the provided filing.
• Footnotes of note:
  • Vesting (F1): Options vest in full on the earlier of the first anniversary of grant or the 2027 Annual Meeting, subject to continued service.
  • Beneficial ownership disclaimer (F2): The options are held for one or more investment vehicles managed by Fairmount Funds Management LLC; the reporting person disclaims beneficial ownership and must turn over any net cash or stock to the adviser for the funds.

Context
This was an option grant (award), not an exercise or sale. Because the options are held for Fairmount-managed funds and the director disclaims beneficial ownership, this filing reflects a grant to managed investment vehicles rather than clear personal buying/selling by the director. Grants are common for directors and compensate service; they do not by themselves indicate immediate buying pressure.